Actovegin 40 mg/ml, 10 ml. (5 ampoules)
$69.00
Indications: Metabolic and vascular disorders in the brain (including cerebral insufficiency syndrome, ischemic strokes, traumatic brain injury)
Description
Actovegin 40 mg/ml, 10 ml (5 ampoules)
Indications:
Metabolic and vascular disorders in the brain, such as cerebral insufficiency syndrome, ischemic strokes, or traumatic brain injury can be treated with this medication.
Additionally, treatments for peripheral (arterial and venous) vascular disorders and their consequences, such as arterial angiopathy and crus ulcers, can be beneficial. Actovegin can also aid in wound healing for ulcers of various etiologies, trophic disorders, and secondary healing processes. Other indications include skin transplantations, thermal and chemical burns, radiation damage to the skin, mucous membranes, and nervous tissue, as well as hypoxia and ischemia of various organs and tissues, and their consequences.
Contraindications:
Pulmonary edema; oliguria; anuria; fluid retention; decompensated heart failure (solution for infusions); hypersensitivity to the drug.
Doses and route of administration depend on the severity of the disease and the indications.
The solution for injection is administered intramuscularly, intravenously or intraarterially. Depending on the severity of the disease, initially 10-20 ml of the injection solution is administered intravenously or intraarterially, and further 5 ml are administered intravenously (slowly) or intramuscularly daily or several times a week.
In circulatory disorders and metabolic issues in the brain, 10 ml is initially administered intravenously daily for two weeks, followed by 5-10 ml intravenously several times a week for the next four weeks.
In the event of an ischemic stroke, 20-50 ml should be diluted in 200-300 ml of infusion solution and injected intravenously daily or several times a week for two to three weeks.
Actovegin Therapy Guidelines
Actovegin is a medication that can be used to treat various medical conditions. Below are the recommended guidelines for administering Actovegin:
Arterial Angiopathy
For arterial angiopathy, 20-50 ml of Actovegin should be diluted in an infusion solution and injected either intraarterially or intravenously daily or several times a week. The average duration of treatment is four weeks.
Trophic and Other Sluggish Ulcers or Burns
For trophic and other sluggish ulcers or burns, 10 ml of Actovegin should be injected intravenously or 5 ml intramuscularly daily or several times a day in conjunction with local therapy with Actovegin.
Radiation Lesions of the Skin and Mucous Membranes
To prevent and treat radiation lesions of the skin and mucous membranes, an average of 5 ml of Actovegin is administered intravenously daily in the intervals between radiation exposure.
For cystitis due to radiation, 10 ml of Actovegin 40 mg/ml is administered transurethrally in the form of an injection solution with an active substance content of 400 mg/10 ml daily in combination with antibacterial therapy.
Disorders of the Blood Supply and Metabolism of the Brain
In the case of disorders of the blood supply and metabolism of the brain, 250–500 ml/day intravenous injection is first administered for 2 weeks, then 250 ml intravenously several times a week for at least 4 weeks.
In ischemic stroke, 250-500 ml is administered intravenously daily or several times a week for about 2-3 weeks.
Actovegin Solution Administration Guidelines
It is recommended to inject no more than 5 ml of Actovegin intramuscularly.
Actovegin solutions for injections are compatible with isotonic sodium chloride solution and 5% dextrose solution (base solutions). For infusion, 10-50 ml of the solution for injection should be diluted in 200-300 ml of the base solution. The infusion rate should be around 2 ml per minute for optimal effectiveness.
Overall, Actovegin therapy can be highly effective in treating a range of conditions. However, it is important to follow the recommended guidelines for administration and dosage in order to achieve the best possible results.
Check also Discussions page
